INTRODUCTION: The identification of type 1 diabetes at an early presymptomatic stage has clinical benefits. These include a reduced risk of diabetic ketoacidosis (DKA) at the clinical manifestation of the disease and a significant reduction in clinical symptoms. The European action for the Diagnosis of Early Non-clinical Type 1 diabetes For disease Interception (EDENT1FI) represents a pioneering effort to advance early detection of type 1 diabetes through public health screening. With the EDENT1FI Master Protocol, the project aims to harmonise and standardise screening for early-stage type 1 diabetes and care. METHODS AND ANALYSIS: Public health islet autoantibody screening is conducted in the Czech Republic, Denmark, Germany, Italy, Poland, Portugal, Sweden and the UK. Between November 2023 (start date) and October 2028 (planned end date), an estimated number of 200 000 children and adolescents aged 1-17 years are expected to be screened. Screening is performed in capillary blood, examining different islet autoantibodies (autoantibodies against insulin, glutamic acid decarboxylase-65, insulinoma-associated antigen-2 and/or zinc transporter-8). Positive screening results undergo confirmation through a second antibody method. A second (venous) blood sample is requested if at least two autoantibodies are detected, to confirm the autoantibody status. Children and adolescents with confirmed two or more autoantibodies are invited to metabolic staging (oral glucose tolerance test, haemoglobin A1c (HbA1c), random glucose, optionally continuous glucose monitoring); an educational programme and recommendations for monitoring are provided. The feasibility and acceptability of screening are evaluated by feedback questionnaires. Pseudonymised data is collated in the EDENT1FI Registry. Study outcomes include country-specific screening rates, prevalences of stage 1 and stage 2 type 1 diabetes, number in EDENT1FI Registry, proportion with DKA and symptoms at clinical diagnosis and median HbA1c. ETHICS AND DISSEMINATION: Following the EDENT1FI Master Protocol, site-specific protocols are developed and approved by local ethics committees (Technical University of Munich, Medical Faculty, Nr. 70/14; Medizinische Hochschule Hannover, Nr. 9588_BO_S_2021; Technische Universität Dresden, Nr. BO-EK-356082020; Center for Sundhed Region Hovedstaden, Nr. H-22053116; Swedish Ethical Review Authority, Nr. 2023-00312-01; National Health Service Health Research Authority and Health Care Research Wales, IRAS (Integrated Research Application System) project ID 309252; Italian National Institute of Health, National ethics committee for clinical trials of public research bodies (EPR) and other national public institutions, Prot. PRE BIO CE Nr. 0059835; Charles University in Prague, Ethics Committee for Multi-Centric Clinical Trials of the University Hopital Motol and 2nd Faculty of Medicine, Nr. 1271/23; Bioethics Committee at the Medical University of Warsaw, Nr. 21/2024 and KB/6/R/2024; Associação Protectora dos Diabéticos de Portugal, Nr. 211/2024). Results are disseminated through peer-reviewed journals and conference presentations and will be shared openly.

Center for Regenerative Therapies Dresden Faculty of Medicine TU Dresden Dresden Germany

Department of Children's Diabetology Faculty of Medical Sciences in Katowice Medical University of Silesia Katowice Poland

Department of Chronic Diseases and Metabolism KU Leuven Leuven Belgium

Department of Clinical Research Translational Type 1 Diabetes Research Steno Diabetes Center Copenhagen Herlev Denmark

Department of Endocrinology University Hospitals Leuven Leuven Belgium

Department of Pediatrics 2nd Faculty of Medicine Charles University Prague and Motol University Hospital Prague Czech Republic

Department of Pediatrics Medical University of Warsaw Warsaw Poland

Diabetes Research Institute IRCCS Ospedale San Raffaele Milan Italy

Education and Research Center APDP Diabetes Portugal Lisbon Portugal

Forschergruppe Diabetes at Klinikum Rechts der Isar Technical University of Munich School of Medicine Munich Germany

Institute of Diabetes Research Helmholtz Munich German Research Center for Environmental Health Munich Germany

Kinderkrankenhaus auf der Bult Hanover Germany

NOVA Medical School Faculdade de Ciências Médicas Universidade Nova de Lisboa Lisbon Portugal

Novo Nordisk A S Soeborg Denmark

University of Birmingham Birmingham UK

Vita Salute San Raffaele University Milan Italy

Zobrazit více v PubMed

Rawshani A, Sattar N, Franzén S, et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet. 2018;392:477–86. doi: 10.1016/S0140-6736(18)31506-X. PubMed DOI PMC

Gregory GA, Robinson TIG, Linklater SE, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022;10:741–60. doi: 10.1016/S2213-8587(22)00218-2. PubMed DOI

Cherubini V, Grimsmann JM, Åkesson K, et al. Temporal trends in diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes between 2006 and 2016: results from 13 countries in three continents. Diabetologia. 2020;63:1530–41. doi: 10.1007/s00125-020-05152-1. PubMed DOI PMC

Fredheim S, Johannesen J, Johansen A, et al. Diabetic ketoacidosis at the onset of type 1 diabetes is associated with future HbA1c levels. Diabetologia. 2013;56:995–1003. doi: 10.1007/s00125-013-2850-z. PubMed DOI

Duca LM, Wang B, Rewers M, et al. Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes Predicts Poor Long-term Glycemic Control. Diabetes Care. 2017;40:1249–55. doi: 10.2337/dc17-0558. PubMed DOI

Duca LM, Reboussin BA, Pihoker C, et al. Diabetic ketoacidosis at diagnosis of type 1 diabetes and glycemic control over time: The SEARCH for diabetes in youth study. Pediatr Diabetes. 2019;20:172–9. doi: 10.1111/pedi.12809. PubMed DOI PMC

Cameron FJ, Scratch SE, Nadebaum C, et al. Neurological consequences of diabetic ketoacidosis at initial presentation of type 1 diabetes in a prospective cohort study of children. Diabetes Care. 2014;37:1554–62. doi: 10.2337/dc13-1904. PubMed DOI PMC

Ghetti S, Kuppermann N, Rewers A, et al. Cognitive Function Following Diabetic Ketoacidosis in Children With New-Onset or Previously Diagnosed Type 1 Diabetes. Diabetes Care. 2020;43:2768–75. doi: 10.2337/dc20-0187. PubMed DOI PMC

Ghetti S, Kuppermann N, Rewers A, et al. Cognitive function following diabetic ketoacidosis in young children with type 1 diabetes. Endocrinol Diabetes Metab. 2023;6:e412. doi: 10.1002/edm2.412. PubMed DOI PMC

Besser REJ, Bell KJ, Couper JJ, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Stages of type 1 diabetes in children and adolescents. Pediatr Diabetes. 2022;23:1175–87. doi: 10.1111/pedi.13410. PubMed DOI

Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309:2473–9. doi: 10.1001/jama.2013.6285. PubMed DOI PMC

Bonifacio E. Predicting type 1 diabetes using biomarkers. Diabetes Care. 2015;38:989–96. doi: 10.2337/dc15-0101. PubMed DOI

Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38:1964–74. doi: 10.2337/dc15-1419. PubMed DOI PMC

ElSayed NA, Aleppo G, Aroda VR, et al. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46:S19–40. doi: 10.2337/dc23-S002. PubMed DOI PMC

Raab J, Haupt F, Scholz M, et al. Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open. 2016;6:e011144. doi: 10.1136/bmjopen-2016-011144. PubMed DOI PMC

Amoroso M, Achenbach P, Powell M, et al. 3 Screen islet cell autoantibody ELISA: A sensitive and specific ELISA for the combined measurement of autoantibodies to GAD65, to IA-2 and to ZnT8. Clin Chim Acta. 2016;462:60–4. doi: 10.1016/j.cca.2016.08.013. PubMed DOI

Ziegler A-G, Haupt F, Scholz M, et al. 3 Screen ELISA for High-Throughput Detection of Beta Cell Autoantibodies in Capillary Blood. Diabetes Technol Ther. 2016;18:687–93. doi: 10.1089/dia.2016.0199. PubMed DOI

Bonifacio E, Weiß A, Winkler C, et al. An Age-Related Exponential Decline in the Risk of Multiple Islet Autoantibody Seroconversion During Childhood. Diabetes Care. 2021;44:2260–8. doi: 10.2337/dc20-2122. PubMed DOI PMC

Ghalwash M, Dunne JL, Lundgren M, et al. Two-age islet-autoantibody screening for childhood type 1 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol. 2022;10:589–96. doi: 10.1016/S2213-8587(22)00141-3. PubMed DOI PMC

Vehik K, Lynch KF, Schatz DA, et al. Reversion of β-Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study. Diabetes Care. 2016;39:1535–42. doi: 10.2337/dc16-0181. PubMed DOI PMC

Weiss A, Zapardiel-Gonzalo J, Voss F, et al. Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening. Diabetologia. 2022;65:2121–31. doi: 10.1007/s00125-022-05780-9. PubMed DOI PMC

Ziegler A-G, Kick K, Bonifacio E, et al. Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany. JAMA. 2020;323:339–51. doi: 10.1001/jama.2019.21565. PubMed DOI PMC

Hummel S, Carl J, Friedl N, et al. Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation. Diabetologia. 2023;66:1633–42. doi: 10.1007/s00125-023-05953-0. PubMed DOI PMC

Kick K, Assfalg R, Aydin S, et al. Recruiting young pre-symptomatic children for a clinical trial in type 1 diabetes: Insights from the Fr1da insulin intervention study. Contemp Clin Trials Commun. 2018;11:170–3. doi: 10.1016/j.conctc.2018.08.004. PubMed DOI PMC

Karl FM, Winkler C, Ziegler AG, et al. Costs of Public Health Screening of Children for Presymptomatic Type 1 Diabetes in Bavaria, Germany. Diabetes Care. 2022;45:837–44. doi: 10.2337/dc21-1648. PubMed DOI

Kick K, Hoffmann VS, Lange K, et al. Feasibility and organization of a population-based screening for pre-symptomatic type 1 diabetes in children — evaluation of the Fr1da study. J Public Health (Berl) 2019;27:553–60. doi: 10.1007/s10389-018-0981-x. DOI

Hummel S, Friedl N, Winkler C, et al. Presymptomatic type 1 diabetes and disease severity at onset. Diabetologia. 2023 doi: 10.1007/s00125-023-06017-z. PubMed DOI PMC

Schneider J, Gemulla G, Kiess W, et al. Presymptomatic type 1 diabetes and disease severity at onset. Diabetologia . 2023;66:2387–8. doi: 10.1007/s00125-023-05999-0. PubMed DOI PMC

Barker JM, Goehrig SH, Barriga K, et al. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care. 2004;27:1399–404. doi: 10.2337/diacare.27.6.1399. PubMed DOI

Elding Larsson H, Vehik K, Bell R, et al. Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care. 2011;34:2347–52. doi: 10.2337/dc11-1026. PubMed DOI PMC

Winkler C, Schober E, Ziegler AG, et al. Markedly reduced rate of diabetic ketoacidosis at onset of type 1 diabetes in relatives screened for islet autoantibodies. Pediatr Diabetes. 2012;13:308–13. doi: 10.1111/j.1399-5448.2011.00829.x. PubMed DOI

Jacobsen LM, Vehik K, Veijola R, et al. Heterogeneity of DKA Incidence and Age-Specific Clinical Characteristics in Children Diagnosed With Type 1 Diabetes in the TEDDY Study. Diabetes Care. 2022;45:624–33. doi: 10.2337/dc21-0422. PubMed DOI PMC

Wentworth JM, Oakey H, Craig ME, et al. Decreased occurrence of ketoacidosis and preservation of beta cell function in relatives screened and monitored for type 1 diabetes in Australia and New Zealand. Pediatr Diabetes. 2022;23:1594–601. doi: 10.1111/pedi.13422. PubMed DOI PMC

Hekkala AM, Ilonen J, Toppari J, et al. Ketoacidosis at diagnosis of type 1 diabetes: Effect of prospective studies with newborn genetic screening and follow up of risk children. Pediatr Diabetes. 2018;19:314–9. doi: 10.1111/pedi.12541. PubMed DOI

Karges B, Prinz N, Placzek K, et al. A Comparison of Familial and Sporadic Type 1 Diabetes Among Young Patients. Diabetes Care. 2021;44:1116–24. doi: 10.2337/dc20-1829. PubMed DOI

Steck AK, Larsson HE, Liu X, et al. Residual beta-cell function in diabetes children followed and diagnosed in the TEDDY study compared to community controls. Pediatr Diabetes. 2017;18:794–802. doi: 10.1111/pedi.12485. PubMed DOI PMC

Lundgren M, Jonsdottir B, Elding Larsson H, et al. Effect of screening for type 1 diabetes on early metabolic control: the DiPiS study. Diabetologia. 2019;62:53–7. doi: 10.1007/s00125-018-4706-z. PubMed DOI PMC

Steffes MW, Sibley S, Jackson M, et al. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care. 2003;26:832–6. doi: 10.2337/diacare.26.3.832. PubMed DOI

Lachin JM, McGee P, Palmer JP, et al. Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes. 2014;63:739–48. doi: 10.2337/db13-0881. PubMed DOI PMC

Gubitosi-Klug RA, Braffett BH, Hitt S, et al. Residual β cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia. J Clin Invest. 2021;131:e143011. doi: 10.1172/JCI143011. PubMed DOI PMC

Herold KC, Bundy BN, Long SA, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019;381:603–13. doi: 10.1056/NEJMoa1902226. PubMed DOI PMC

Sims EK, Bundy BN, Stier K, et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med. 2021;13:eabc8980. doi: 10.1126/scitranslmed.abc8980. PubMed DOI PMC

Hagopian W, Ferry RJ Jr, Sherry N, et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 2013;62:3901–8. doi: 10.2337/db13-0236. PubMed DOI PMC

Herold KC, Gitelman SE, Ehlers MR, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013;62:3766–74. doi: 10.2337/db13-0345. PubMed DOI PMC

Herold KC, Gitelman SE, Willi SM, et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia. 2013;56:391–400. doi: 10.1007/s00125-012-2753-4. PubMed DOI PMC

Perdigoto AL, Preston-Hurlburt P, Clark P, et al. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. Diabetologia. 2019;62:655–64. doi: 10.1007/s00125-018-4786-9. PubMed DOI PMC

Marzinotto I, Pittman DL, Williams AJK, et al. Islet Autoantibody Standardization Program: interlaboratory comparison of insulin autoantibody assay performance in 2018 and 2020 workshops. Diabetologia. 2023;66:897–912. doi: 10.1007/s00125-023-05877-9. PubMed DOI PMC

Lampasona V, Pittman DL, Williams AJ, et al. Islet Autoantibody Standardization Program 2018 Workshop: Interlaboratory Comparison of Glutamic Acid Decarboxylase Autoantibody Assay Performance. Clin Chem. 2019;65:1141–52. doi: 10.1373/clinchem.2019.304196. PubMed DOI PMC

Lampasona V, Schlosser M, Mueller PW, et al. Diabetes antibody standardization program: first proficiency evaluation of assays for autoantibodies to zinc transporter 8. Clin Chem. 2011;57:1693–702. doi: 10.1373/clinchem.2011.170662. PubMed DOI

Hendriks AEJ, Marcovecchio ML, Besser REJ, et al. Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes. Diabetes Metab Res Rev. 2024;40:e3777. doi: 10.1002/dmrr.3777. PubMed DOI

Hummel M, Ziegler AG, Roth R. Psychological impact of childhood islet autoantibody testing in families participating in the BABYDIAB study. Diabet Med. 2004;21:324–8. doi: 10.1111/j.1464-5491.2004.01142.x. PubMed DOI

Johnson SB, Lynch KF, Roth R, et al. My Child Is Islet Autoantibody Positive: Impact on Parental Anxiety. Diabetes Care. 2017;40:1167–72. doi: 10.2337/dc17-0166. PubMed DOI PMC

Bennett Johnson S, Tercyak KP., Jr Psychological impact of islet cell antibody screening for IDDM on children, adults, and their family members. Diabetes Care. 1995;18:1370–2. doi: 10.2337/diacare.18.10.1370. PubMed DOI

Galatzer A, Green E, Ofan R, et al. Psychological impact of islet cell antibody screening. J Pediatr Endocrinol Metab. 2001;14 Suppl 1:675–9. doi: 10.1515/jpem.2001.14.s1.675. PubMed DOI